Sapiens is a medical technology company developing Steering Brain Stimulation implant and procedure solutions aimed at treating Parkinson’s disease and other functional brain disorders. The company’s work focuses on next‑generation deep brain stimulation (DBS) systems that deliver targeted electrical pulses via implanted leads and pulse generators. Proceeds from the recent financing will be used to advance development of its implant and procedural offerings. Sapiens has previously secured institutional Series A funding and this additional investment supplements that initial round, supporting continued product development and commercialization efforts. The article notes that DBS is already approved in Europe for Parkinson’s, essential tremor, dystonia, OCD and, more recently, epilepsy, and that clinical groups are exploring DBS for other neurological and psychiatric indications. Management frames the new investment as validation of the therapeutic and commercial potential of Sapiens’ steering DBS technologies. Sapiens Steering Brain Stimulation, founded in 2011 as a spin‑out of Royal Philips Electronics, builds high-resolution, thin-film based probes and an integrated image-based suite (SurePlan, SurePlace, SureTune) to plan and program DBS treatments. Its SureStim implant is MRI-conditionally safe and the platform steers tiny stimulation currents to reduce side effects and improve patient comfort. The company aims to shorten and simplify DBS procedures while improving therapeutic outcomes. Sapiens is developing its Steering Brain Stimulation proposition to treat Parkinson’s disease and other brain disorders in collaboration with clinical partners including the Academic Medical Center Amsterdam and TMSi. Leadership includes CEO Sjaak Deckers and CTO Michel Decré, and the company has offices in Eindhoven and Munich. The business is supplementing prior financing to advance its high-resolution probe and procedure solutions. Sapiens develops solutions for deep brain stimulation (DBS) therapy, including implants and navigation/steering software. Its DBS system is designed to create a patient-specific brain map and support surgeons in finding the ideal trajectory while avoiding critical structures. The technology aims to enable accurate placement of electrodes in target brain areas. The company intends to use the €13m Series A funds to further develop its brain stimulation system and software. DBS is applied for essential tremor, late-stage Parkinson’s disease, dystonia, obsessive-compulsive disorder and epilepsy, and Sapiens says the therapy may expand to other neurologic or psychiatric indications. Sapiens was founded in 2011 as a spin-off from Royal Philips Electronics and is based in Eindhoven, The Netherlands.

Total raised

$42M

Funding rounds

6

Latest round

Series A

Latest activity

Feb 2013